US Patent

US10357616 — Injection device with an end of dose feedback mechanism

Formulation · Assigned to Novo Nordisk AS · Expires 2026-01-20 · 0y expired

Vulnerability score 28/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an injection device with an end of dose feedback mechanism suitable for injecting insulin.

USPTO Abstract

The injection device is suitable for injecting insulin.

Drugs covered by this patent

Patent Metadata

Patent number
US10357616
Jurisdiction
US
Classification
Formulation
Expires
2026-01-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.